SEARCH

SEARCH BY CITATION

References

  • Ataga, K.I., Orringer, E.P., Styles, L., Vichinsky, E.P., Swerdlow, P., Davis, G.A., Desimone, P.A. & Stocker, J.W. (2006) Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy, 26, 15571564.
  • Ataga, K.I., Smith, W.R., De Castro, L.M., Swerdlow, P., Saunthararajah, Y., Castro, O., Vichinsky, E., Kutlar, A., Orringer, E.P., Rigdon, G.C. & Stocker, J.W. (2008) Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood, 111, 39913997.
  • Brugnara, C., de Franceschi, L. & Alper, S.L. (1993) Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. The Journal of Clinical Investigation, 92, 520526.
  • Cala, P. (1983) Volume regulation by red blood cells: mechansims of ion transport. Molecular Physiology, 4, 3352.
  • Canessa, M. (1991) Red cell volume-related ion transport systems in hemoglobinopathies. Hematology/Oncology Clinics of North America, 5, 495516.
  • De Franceschi, L., Saadane, N., Trudel, M., Alper, S.L., Brugnara, C. & Beuzard, Y. (1994) Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. The Journal of Clinical Investigation, 93, 16701676.
  • Eaton, W.A., Hofrichter, J. & Ross, P.D. (1976) Editorial: delay time of gelation: a possible determinant of clinical severity in sickle cell disease. Blood, 47, 621627.
  • Ishii, T.M., Silvia, C., Hirschberg, B., Bond, C.T., Adelman, J.P. & Maylie, J. (1997) A human intermediate conductance calcium-activated potassium channel. Proceedings of the National Academy of Sciences, 94, 1165111656.
  • Kaul, D.K. (2008) Sickle red cell adhesion: many issues and some answers. Transfusion Clinique et Biologique, 15, 5155.
  • Machado, R.F., Barst, R.J., Yovetich, N.A., Hassell, K.L., Goldsmith, J.C., Woolson, R., Gordeuk, V.R., Gibbs, S., Little, J.A., Kato, G.J., Schraufnagel, D.E., Krishnamurti, L., Girgis, R.E., Morris, C.R., Berman-Rosenzweig, E., Badesch, D.B., Myron, A., Waclawiw, M.A. & Gladwin, M. (2009) Safety and efficacy of sildenafil therapy for Doppler-defined pulmonary hypertension in patients with sickle cell disease: preliminary results of the Walk-PHaSST clinical trial. Blood (ASH Annual Meeting Abstracts), 114, 571.
  • McNaughton-Smith, G.A., Burns, J.F., Stocker, J.W., Rigdon, G.C., Creech, C., Arrington, S., Shelton, T. & de Franceschi, L. (2008) Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. Journal of Medicinal Chemistry, 51, 976982.
  • Okpala, I., Daniel, Y., Haynes, R., Odoemene, D. & Goldman, J. (2002) Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. European Journal of Haematology, 69, 135144.
  • Platt, O.S., Thorington, B.D., Brambilla, D.J., Milner, P.F., Rosse, W.F., Vichinsky, E. & Kinney, T.R. (1991) Pain in sickle cell disease. Rates and risk factors. New England Journal of Medicine, 325, 1116.
  • Schmidtko, A., Tegeder, I. & Geisslinger, G. (2009) No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing Trends in Neurosciences, 32, 339346.
  • Stocker, J.W., De Franceschi, L., McNaughton-Smith, G.A., Corrocher, R., Beuzard, Y. & Brugnara, C. (2003) ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood, 101, 24122418.
  • Stuart, M.J. & Nagel, R.L. (2004) Sickle-cell disease. Lancet, 364, 13431360.